Anaplastic oligodendroglioma: Advances and treatment options

Current Treatment Options in Neurology

Volumn 15, Issue 3, 2013, Pages 289-301

  McNamara, Mairéad G ^a   Sahebjam, Solmaz ^a   Mason, Warren P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

1p19q codeletion; Advances; Anaplastic oligodendroglioma; Antiangiogenic therapy; Chemotherapy; IDH1 mutations; Lomustine; MGMT promoter methylation; Procarbazine; Radiotherapy; Surgery; Temozolomide; Treatment; Vincristine

Indexed keywords

APREPITANT; BEVACIZUMAB; CARBAMAZEPINE; CARBOPLATIN; CARMUSTINE; CLARITHROMYCIN; DILTIAZEM; ETOPOSIDE; FLUOXETINE; FLUVOXAMINE; GADOLINIUM; IRINOTECAN; ISOCITRATE DEHYDROGENASE 1; KETOCONAZOLE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PANITUMUMAB; PROCARBAZINE; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFAMPICIN; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; VINCRISTINE;

ABDOMINAL CRAMP; ACUTE GRANULOCYTIC LEUKEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRAIN ABSCESS; BRAIN HEMORRHAGE; BRAIN INFECTION; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; COGNITIVE DEFECT; CONSTIPATION; CONTRAST ENHANCEMENT; CPG ISLAND; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DNA METHYLATION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; HAIR LOSS; HETEROZYGOSITY LOSS; HUMAN; HYPERTENSION; INFERTILITY; INTRACRANIAL HYPERTENSION; KIDNEY DYSFUNCTION; LACRIMATION; LIQUORRHEA; LIVER DYSFUNCTION; METALLIC TASTE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROIMAGING; NEUROLOGIC DISEASE; OCCUPATIONAL THERAPY; OLIGODENDROGLIOMA; OTOTOXICITY; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; POINT MUTATION; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION NECROSIS; RECOMMENDED DRUG DOSE; REOPERATION; RHINORRHEA; SIDE EFFECT; SPEECH THERAPY; SWEATING; TASTE; THROMBOSIS; WOUND HEALING IMPAIRMENT;

EID: 84878321480     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0218-9     Document Type: Article

References (47)

1. Central Brain Tumor Registry of the United States. Statistical report: primary brain tumors in the United States, 1998-2002 (Central Brain Tumor Registry of the United States, Hinsdale, IL. 2005.
2. Kleihues P, Burger PC, Aldape KD, et al. In: Louis DN, Ohgaki H, Wiester OD, et al., editors. WHO classification of tumors of the central nervous system, glioblastoma. Lyon: IARC; 2007. p. 33-49.
3. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482-90.
4. Suri V, Jha P, Agarwal S, et al. Molecular profile of oligodendrogliomas in young patients. Neuro Oncol. 2011;13(10):1099-106.
5. Fisher JL, Schwartzbaum JA, Wrensch M, et al. Epidemiology of brain tumors. Neurol Clin. 2007;25(4):867-90.
6. Mirsattari SM, Chong JJ, Hammond RR, et al. Do epileptic seizures predict outcome in patients with oligodendroglioma? Epilepsy Res. 2011;94(1-2):39-44.
7. Jenkinson MD, du Plessis DG, Smith TS, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 2006;129(Pt 7):1884-91.
8. Zagzag D, Goldenberg M, Brem S. Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. Am J Roentgenol. 1989;153(1):141-6.
9. White ML, Zhang Y, Kirby P, et al. Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? Am J Neuroradiol. 2005;26(4):784-90.
10. Sankar T, Moore NZ, Johnson J, et al. Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. J Neurosurg. 2012;116(6):1172-81.
11. Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res. 2004;10(13):4303-6.
12. Jenkins RB, Blair H, Ballma KV, et al. A t(1,19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20):9852-61.
13. Alentorn A, Sanson M, Idbaih A. Oligodendrogliomas: new insights from the genetics and perspectives. Curr Opin Oncol. 2012;24(6):687-93.
14. Xiong J, Liu Y, Wang Y, et al. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas. Chin Med J. 2010;123(24):3566-73.
15. Scheie D, Meling TR, Cvancarova M, et al. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol. 2011;13(11):1225-33.
16. Horbinski C, Hobbs J, Cieply K, et al. EGFR expression stratifies oligodendroglioma behavior. Am J Pathol. 2011;179(4):1638-44.
17. Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One. 2012;5(9):e12548.
18. Gerson SL. MGMT: its role in cancer etiology and cancer therapeutics. Nat Rev. 2004;4(4):296-307.
19. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27(35):5881-6.
20. van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clin Cancer Res. 2011;17(22):7148-55.
21. Ramirez C, Bowman C, Maurage CA, et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors - towards individualized tumor treatment. Neuro Oncol. 2010;12(5):490-9.
22. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-73.
23. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16(5):1597-604.
24. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-43. This article provided long term follow up data on RTOG 9402 and concludes that for the subset of patients with codeleted 1p19q anaplastic oligodendrogliomas, PCV plus radiotherapy may be an especially effective treatment.
25. van den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-50. This article provides long term follow up data on EORTC 26951 and concludes that the addition of 6 cycles of PCV after 59.4 Gy of radiotherapy increases both overall survival and progression free survival in anaplastic oligodendroglioma tumors and 1p19q codeleted tumors derive more benefit than non 1p19q deleted tumors.
26. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011;13(6):649-59.
27. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-80.
28. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007;9(3):314-8.
29. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide vs radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-66.
30. Li S, Yan C, Huang L, et al. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol. 2012;14(1):109-16.
31. Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology. 2004;63(5):904-6.
32. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19(9):2449-55.
33. Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009;115(8):1734-43.
34. Taillibert S, Vincent LA, Granger B, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology. 2009;72(18):1601-6.
35. Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J Clin Oncol. 1997;15(12):3427-32.
36. Soffietti R, Nobile M, Ruda R, et al. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer. 2004;100(4):807-13.
37. Scopece L, Franceschi E, Cavallo G, et al. Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. J Neurooncol. 2006;79(3):299-305.
38. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-44.
39. Niyazi M, Maihoefer C, Krause M, et al. Radiotherapy and "new" drugs-new side effects? Radiat Oncol. 2011;6:177.
40. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465-77.
41. Sinclair AG, Scoffings DJ. Imaging of the post-operative cranium. Radiographics. 2010;30(2):461-82.
42. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):2707-14.
43. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715-22.
44. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076-84.
45. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow up of a multicenter controlled trial. Acta Neurochir. 2006;148(3):269-75.
46. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10 year institutional experience. Ann Surg Oncol. 2008;15(10):2887-93.
47. Westphal M, Hilt DC, Bortey E, et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.